CyberKnife® Research at the Capital Health Center for Oncology
Research and clinical trials in oncology at Capital Health Center for Oncology is a major part of the total medical care we offer our patients. Due to the relatively new emergence of CyberKnife® radiosurgery in oncology and neurosurgery, ongoing research using this device is still active and therefore there are many national protocols that are available to our patients.
Over the past two years, we have identified and initiated protocols that investigate improved treatment methodology and efficiency for all patients using CyberKnife radiosurgery. Some of the protocols we have opened included treatment for brain, prostate and spine tumors, and in the next few months, we will start new CyberKnife clinical trials that involve treatment to prostate and spinal metastases.
To better serve our cancer patient population, we have also instituted several research studies that evaluate our treatment methods and outcomes. Listed below are the protocols and studies that are currently open for enrollment of patients.
Current Active Clinical Trials:
CK Brain Mets-01- A Phase II consensus multi-institutional trial of CyberKnife Radiosurgery to the operative cavity in patients with resected brain metastases.
Sex: Male or Female
Age: 18 years of age and older
Histology: Brain metastases of malignant epithelial cell origin, excluding small cell carcinoma, lymphoma, germ cell tumors, leukemia, and multiple myeloma.
Number of Brain Mets: 1-3
Size of Planning Target Volume: less than or equal to 5.0 cm
KPS: greater than or equal to 70
Surgery: All patients will have undergone craniotomy with a gross total resection per the attending neurosurgeon’s assessment and confirmed by a CyberKnife planning brain MRI.
Radiation: Prior whole-brain XRT or prior stereotactic radiosurgery to the resection cavity area are exclusion criteria. Prior stereotactic radiosurgery to other parts of the brain is NOT an exclusion criterion.
Number of Subjects: 20
RTOG 0938 - A randomized Phase II trial of hypofractionated radiotherapy for favorable risk prostate cancer.
RTOG 0631 - A Phase II/III study of image-guided radiosurgery/SBRT for localized spine metastasis.
For more information regarding clinical trials, please contact:
Research Nurse: Linda Andrzejewski, RN, at (609) 537-7042 or e-mail email@example.com